Company intelligence / Profile preview

Phairson

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Phairson was a UK-based biotechnology company focused on the development of novel therapies for the prevention and treatment of bacterial infections, specifically those caused by Staphylococcus aureus. The company's lead candidate, PST-01, was a recombinant protein designed to prevent S. aureus infections in surgical settings by targeting specific surface proteins of the bacteria. Phairson's approach aimed to address the growing clinical challenge of antibiotic-resistant strains like MRSA. The company was acquired in 2003 by the Swiss biopharmaceutical firm Arpida AG to bolster its anti-infective pipeline.

Therapeutic areas: Infectious Diseases
Modalities: Recombinant proteinProtein
Industry: Biotech

Beyond the preview

Go deeper on Phairson.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phairson.

Explore the full profile